inebilizumab (Uplizna) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Breakthrough Therapy FDA

Active Ingredient History

  • Now
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$32772.1300 - $43666.6633
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

188-0551 | inebilizumab | medi-551


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue